Browse the corpus

Index Note: Page numbers followed by f and t denote figure and table, respectively. Bone metastases, 44, Q34 Test questions are indicated by Q. Bone-seeking isotopes, 29t Brachytherapy, for prostate cancer, 27 A BRAF mutations, CRC and, 18-19 Abdominal-perineal resection, 17 BRAF V600E mutations, 23, 35, 41 Abiraterone, for castrate-resistant prostate cancer, 28 BRAF/MEK inhibitors, for melanoma, 41 Abiraterone plus prednisone, 29t BRCA 1/2 mutations Acneiform eruptions, 45 breast cancer and, 5, 7, 13 Acute tubular necrosis, cisplatin and, 46 ovarian cancer and, 14, Q15 Adjuvant chemotherapy, 11, 22 prostate cancer and, 26, 27, Q30 Adjuvant endocrine therapy, 10-11 Breast and ovarian cancer syndrome, 6t Ado-trastuzumab-emtansine conjugate, 11, 13 Breast cancer Adrenalitis, chemotherapy and, 46 adjuvant systemic therapy for, 10-11 ADT. See Androgen deprivation therapy (ADT) chemoprevention of, 5-7, 8t, Q60 Age/aging diagnosis of, Q3 invasive breast cancer management and, 10 early, prognosis of, 7-9 treatment decisions and, 2 epidemiology of, 5 Alectinib, for NSCLC, Q46 follow-up, 12-13 Alemtuzumab, for CLL, 34 HER2 expression in, 4 ALK mutations, 23, 37, Q46 imaging guidelines, Q3 Alkylating agents, for CLL, 34 inflammatory, 12, 12f, Q20, Q40 Alopecia, chemotherapy and, 45 invasive, 8t, 9-10, Q67 a-fetoprotein marker, for testicular cancer, 29-30 locally advanced, 12 Amoxicillin/clavulanate, for neutropenia and fever, 45, Q33 metastatic, 13-14, Q12, Q34 Anal cancer, 19, Q22 MRI screening for, 7t Analgesia, treatment goals and, 3 multigene assays and prognosis, 4 Anaplastic large cell lymphomas, 37 multigene recurrence assay, Q45 Anaplastic T-cell lymphomas, diagnosis of, Q35 node-negative, 11 Anastrozole, 7, 8t, 9 nonmetastatic, 10-11 Androgen deprivation therapy (ADT), 28-29, 47, Q23, Q39. risk factors for, 5, 6t See also Antiandrogen therapy risk reduction strategies, 5-7 Androgen receptor blockade, for prostate cancer, 29t screening for, Q31 Anemia, chemotherapy and, 45 sequence of treatment in, Q20 Angioimmunoblastic T-cell lymphoma, 37 staging of, 7-9 Ann Arbor staging system, 32, 33f survivorship, 12-13 Anthracyclines, adverse effects of, 46 triple-negative, 13-14 Antiandrogen therapy, 9-10, 29t. See also Androgen deprivation Breast implants, textured, Q35 therapy (ADT) Breast reconstructive surgery, 12 Antiepileptic drugs, for increased ICP, 43 Brentuximab vedotin, for HL, 38-39 Antiestrogen therapy, in breast cancer, 11 Bruton kinase inhibitors, for CLL, 34 Antigen-4 (A-4) molecule, 5 Bupropion, mechanism of action, 12 Apalutamide, for metastatic prostate cancer, 29t Burkitt lymphoma, 32, 36 Aprepitant, for nausea and vomiting, 45, Q42 Buserelin, for metastatic prostate cancer, 29t Aromatase inhibitors, 10, 47, Q48, Q60 Atezolizumab, 5, 13, 46 Cc ATM mutations, prostate cancer and, 26 CA-15-3, 39 Atypical hyperplasia, breast cancer and, 5 CA-19, 39 Atypical small acinar proliferation, 27 CA-125, 14, 15, 39 Autoimmune disorders, lymphoma and, 32 Cabazitaxel plus prednisone, for prostate cancer, 29t Avelumab, adverse effects of, 46 Calcitonin, 44 Axillary dissection, indications for, 9-10 Calcium supplementation, 28, 46 Cancer of unknown primary (CUP), 39-40, Q5. Q7, Q44 B Capecitabine. See also CAPOX regimen Barrett esophagus, 20 adverse effects of, 45 B-cell lymphomas, 32, 35-36 for metastatic breast cancer, 13 BCL2 oncogene overexpression, 33 for pancreatic cancer, 20 BCL6 gene, 35 for pancreatic neuroendocrine tumors, 21 Bendamustine, 33, 34, 36 for rectal cancer, 18 Benzodiazepines, for nausea and vomiting, 45 CAPOX regimen, 18 Bevacizumab, 18-19, 23, 46 Carboplatin, for testicular cancer, 30 Bicalutamide, for metastatic prostate cancer, 29t Carcinoembryonic antigen (CEA) levels, 17, 18, 39 Biopsies Cardiac function in cancer survivors, 46-47 excisional, 32 Cardiac tamponade, 43 indications for, Q12, Q18 Cardiomyopathies, chemotherapy and, 46 neck mass, Q66 CD19, 34 tumor seeding and, 29-30 CD20, 34 Birth defects, risk of, Q16 CD23, 34 Bisphosphonates, 28, 44, 46, 46f CD30, 37 Bladder cancer, hematuria in, 31 CDKN2A mutations, 41 Bleomycin, pulmonary toxicity of, 45-46 CEA. See Carcinoembryonic antigen (CEA) levels Bone loss, 46, Q14, Q48 Cefepime, for neutropenia and fever, 45

Note: Page numbers followed by f and t denote figure and table, respectively. Bone metastases, 44, Q34 Test questions are indicated by Q. Bone-seeking isotopes, 29t Brachytherapy, for prostate cancer, 27 A BRAF mutations, CRC and, 18-19 Abdominal-perineal resection, 17 BRAF V600E mutations, 23, 35, 41 Abiraterone, for castrate-resistant prostate cancer, 28 BRAF/MEK inhibitors, for melanoma, 41 Abiraterone plus prednisone, 29t BRCA 1/2 mutations Acneiform eruptions, 45 breast cancer and, 5, 7, 13 Acute tubular necrosis, cisplatin and, 46 ovarian cancer and, 14, Q15 Adjuvant chemotherapy, 11, 22 prostate cancer and, 26, 27, Q30 Adjuvant endocrine therapy, 10-11 Breast and ovarian cancer syndrome, 6t Ado-trastuzumab-emtansine conjugate, 11, 13 Breast cancer Adrenalitis, chemotherapy and, 46 adjuvant systemic therapy for, 10-11 ADT. See Androgen deprivation therapy (ADT) chemoprevention of, 5-7, 8t, Q60 Age/aging diagnosis of, Q3 invasive breast cancer management and, 10 early, prognosis of, 7-9 treatment decisions and, 2 epidemiology of, 5 Alectinib, for NSCLC, Q46 follow-up, 12-13 Alemtuzumab, for CLL, 34 HER2 expression in, 4 ALK mutations, 23, 37, Q46 imaging guidelines, Q3 Alkylating agents, for CLL, 34 inflammatory, 12, 12f, Q20, Q40 Alopecia, chemotherapy and, 45 invasive, 8t, 9-10, Q67 a-fetoprotein marker, for testicular cancer, 29-30 locally advanced, 12 Amoxicillin/clavulanate, for neutropenia and fever, 45, Q33 metastatic, 13-14, Q12, Q34 Anal cancer, 19, Q22 MRI screening for, 7t Analgesia, treatment goals and, 3 multigene assays and prognosis, 4 Anaplastic large cell lymphomas, 37 multigene recurrence assay, Q45 Anaplastic T-cell lymphomas, diagnosis of, Q35 node-negative, 11 Anastrozole, 7, 8t, 9 nonmetastatic, 10-11 Androgen deprivation therapy (ADT), 28-29, 47, Q23, Q39. risk factors for, 5, 6t See also Antiandrogen therapy risk reduction strategies, 5-7 Androgen receptor blockade, for prostate cancer, 29t screening for, Q31 Anemia, chemotherapy and, 45 sequence of treatment in, Q20 Angioimmunoblastic T-cell lymphoma, 37 staging of, 7-9 Ann Arbor staging system, 32, 33f survivorship, 12-13 Anthracyclines, adverse effects of, 46 triple-negative, 13-14 Antiandrogen therapy, 9-10, 29t. See also Androgen deprivation Breast implants, textured, Q35 therapy (ADT) Breast reconstructive surgery, 12 Antiepileptic drugs, for increased ICP, 43 Brentuximab vedotin, for HL, 38-39 Antiestrogen therapy, in breast cancer, 11 Bruton kinase inhibitors, for CLL, 34 Antigen-4 (A-4) molecule, 5 Bupropion, mechanism of action, 12 Apalutamide, for metastatic prostate cancer, 29t Burkitt lymphoma, 32, 36 Aprepitant, for nausea and vomiting, 45, Q42 Buserelin, for metastatic prostate cancer, 29t Aromatase inhibitors, 10, 47, Q48, Q60 Atezolizumab, 5, 13, 46 Cc ATM mutations, prostate cancer and, 26 CA-15-3, 39 Atypical hyperplasia, breast cancer and, 5 CA-19, 39 Atypical small acinar proliferation, 27 CA-125, 14, 15, 39 Autoimmune disorders, lymphoma and, 32 Cabazitaxel plus prednisone, for prostate cancer, 29t Avelumab, adverse effects of, 46 Calcitonin, 44 Axillary dissection, indications for, 9-10 Calcium supplementation, 28, 46 Cancer of unknown primary (CUP), 39-40, Q5. Q7, Q44 B Capecitabine. See also CAPOX regimen Barrett esophagus, 20 adverse effects of, 45 B-cell lymphomas, 32, 35-36 for metastatic breast cancer, 13 BCL2 oncogene overexpression, 33 for pancreatic cancer, 20 BCL6 gene, 35 for pancreatic neuroendocrine tumors, 21 Bendamustine, 33, 34, 36 for rectal cancer, 18 Benzodiazepines, for nausea and vomiting, 45 CAPOX regimen, 18 Bevacizumab, 18-19, 23, 46 Carboplatin, for testicular cancer, 30 Bicalutamide, for metastatic prostate cancer, 29t Carcinoembryonic antigen (CEA) levels, 17, 18, 39 Biopsies Cardiac function in cancer survivors, 46-47 excisional, 32 Cardiac tamponade, 43 indications for, Q12, Q18 Cardiomyopathies, chemotherapy and, 46 neck mass, Q66 CD19, 34 tumor seeding and, 29-30 CD20, 34 Birth defects, risk of, Q16 CD23, 34 Bisphosphonates, 28, 44, 46, 46f CD30, 37 Bladder cancer, hematuria in, 31 CDKN2A mutations, 41 Bleomycin, pulmonary toxicity of, 45-46 CEA. See Carcinoembryonic antigen (CEA) levels Bone loss, 46, Q14, Q48 Cefepime, for neutropenia and fever, 45 105

9OL 990 ‘SSO ‘1SZ ‘9T-Pz ‘SIaouRd YOaU puR pray 167 ‘JooUBd d}eISOId d1VBISeIDUT IOJ ‘AUOSTUpaid snqd [axejJa0q Gh ‘gI ‘aUIOIPUAS JO0J-pueH 87 ‘EZ “77 “ET “TT “‘Jaxe}a00q JSE “SE “BILUAayNg] [Jao AEH €1 ‘syBoiq pueijs-a[qnop ‘WNC H SaWAZUS (YININP) Jredas yoyeuUsTW JUSIDYeq] 9aS “MINING ZZ ‘SJUaWaInsvawWl ODOT 16% ‘a0Ukd a}e]SOId J1WeISeJOW OJ “UlJa1asOH bb °C UU TAAXOIpAUIP-ST'T 167 ‘6C-8¢ ‘Lz ‘S\stuose (HYUD) UOUWLIOY SUIsea[el-UIdomOpeuoy ¢ (SHA) SUOHeUTUTeXA [POAT [ISIC WZ ‘pue Ia9.uUed aye\so1d ‘sa1O0Ds UOsRa[D S¢-ee ‘eumoydur,y [[99-g- a81e] asNyjIGd 1 *(Stourn) [BUUOT}s [eulsajuTONses) SLSID 60 ‘SI ‘pue Aderoyjoutayp ‘eaysieiq 0z ‘(eseasip xnJor [easeydossoises) CYAD ZrO ‘1ZO ‘Er ‘MUOseyJoWexaq T ‘anss}j 10wWn) “sul[yoid sTwousy Or ‘pure AdedyJOUIdY ‘sHRULIDG TE-97 ‘Iaouerd AreULIMo}Usy 610 ‘pure drysioatains ‘uorssaidaq 0&0 ‘Zr ‘SUTTasUNOD soTJaUsy Or “87 ‘EL ‘Quutnsousd OZ ‘Ta0uRd deaIDUR IO} 16Z ‘JadULd 3}e]SO1d J17R}SPIOUL 10J *xIparesaq €T Tadd JsvaIq IPISBIOW IO} LT ‘sawAzuea (YIP) Iredar yoyeuistu yusoyoq €T ‘TZ “Jaoued Suny I0y | ‘pue sapyoid [euotjenu “suryeul UOTsIIaq 9r-Sh JO Sjoayja asJOApe (SIO) Ns UF BUOUTOIR [e}NC 2ag ‘SIOd auTqeyoWay > ‘Aq UOnIQIUU VU ‘qruayerqeq Sr ‘JO Sjoayja asTaApe ‘qrunyey qa IZ ‘(SLSTD) SIOWIN} [RWOI)s [eUTSayUTONsey tO ‘TZ ‘SIOWIN) SULIDOpUdOINAU [RUT|SaUTONSey 690 ‘Ih 'S yp ‘UT UoTssaidxa TYAH ‘s1ourny jeaseydosaoijsey ‘Spoqnur (p-V'LO) p-uesyue a]A00ydurA-], Fx0}0}AD ISO ‘Jo uoNeNyRAd ‘s1oumn) [easeydosso1sey OF ‘JO SJoa]Ja asIOApe ‘apIsOUTqRIe dUTSO]AD 0Z ‘(AUAD) esvasip xnjJear [easeydossonsey ZO ‘TE ‘Adoodsojskp OZ ‘sIaoued [Raseydossojsey L@ ‘UONCIPRI Jaqye “STTSAD 1z-0z ‘ewoydurAy ase) Tg IO} SUOTJBOTPUT ‘AUIO}D9}SA_, OF ‘JO ALOTXO} STSOTOINA|U ‘ATaSIMS ayTUY, PUTT 16Z ‘Jaoukd a7e]SO1d STVeISPISU 1OJ *“SIONQIYUL ZIAD OID ‘erwUauTTNgosewureSod Ay 10j ‘UIpNgo[s BUTTE UdUISa1 dOHO-z OS]D 2ag “ov ‘SE ‘ve ‘IL ‘apreueydsoydopasg 9 JLE ‘LE-9¢ ‘euoydurAy [[99-], snoaueynD ¢ Jo UONTUYsp ‘and eg ‘sewmmoydu] JeMoyyoy (dNd) Arewid umouyun Jo Jaoue9 aag dno +O ‘81 ‘Uatutsar XOTTOA (P-VTILO) p-Uasyue ayA00ydursT-], 1X0}O}AD 2ag *p-VTLO 16Z ‘Jaoued d}e]SOId STVeISeISUT IOJ ‘AprureNy]y TE-O€ “BWOUTOIkd [[ad [BUA IOJ ‘UOTRTqBOAID ZI ‘UOTe JO WsTURYDeU ‘SUTSxXON] (OUD) J9dUwd [kIDIIOJOD 23g ‘QYO Sp ‘JaAoj puv evluadorneu Joy ‘souojournboson[y IZO ‘onovpAydoid ‘uonerpesm [eresD OF ‘Sf ‘JO S}DayJa asTaApe ‘sauTprulsAdosonyy Or ‘uuseds A1eUOIOD be “TIO Joy ‘ourqerepny] Or ‘pue Adesoyjowlayp ‘Aouatoyynsurt ATRUOIOD UdUIB91 XOATOA OSD 22S “10 ‘OF ‘Sr ‘OZ “ST *(MA-S) [oenoiony-s 0SO ‘9T ‘UonezIuOD 990 ‘ZE ‘Sz ‘ABOfO}AD UOTJeIIdse a[paau-dUTy ¢-Z ‘pue Adesay} Jo seos ‘uot eorUNUTUOD € ‘APOFXo} [eIOUPULy 9&0 ‘ZIO ‘Aderayjoways UoTeUIquIO; € ‘puke s[eos JUSTUJeAI] ‘saNsst [eIOUPUL] LT ‘Wuaueuttad ‘AUIOso[OD 7 ‘syuawaimnseaw 'Aqy UT *6I-LT “ “(OUD) Jou [e}Da10[0D 0S0 ‘620 ‘Zr ‘ATHJet LSO ‘ST ‘Jo surseys | LSO ‘Lr ‘Ul stsouso1d €1O ‘Wealoyeap-iredar yoyeurstu Lg ‘sewoydunAT []29 J, 10J ‘stsaraydojoyd [eatodi0seNxy 9S0 ‘UI UOIssaidxa ula}01d Itedai YoyeUIsTU LZ ‘Iaoued ayeysoid 10} ‘UOT RIPRIIT Weaq [eUID}Xy IrO ‘€1O ‘oneisejou 090 ‘38 ‘Z ‘aueysoWaxy IO Jo JuswaseueUl Tg ‘sIOUIN} SULIDOpUdsOIM|U INeaIDUe IOJ ‘SNUIT[OIDAG PSO ‘Ul Sulseut Ly ‘Adeiay yusutaoe[dai ussonsy +O ‘Joy Aderayjouays 6 ‘Io} aatyIsod S][Oq ‘s10}dade1 Uas01jSy daoued UOTOD €r ‘(UOIssa1dutod p1oo [eulds Tempids) DDSA Or ‘pure AderlayOUayp ‘sHITOD Sp ‘etuadoyAd0quio1y} pue eruaue Ioj ‘uatodomyyA1q Ly ‘9p ‘UoRsuNy aayTUsOD £90 ‘Alepuodas ‘stso} A014 AIA €% ‘Jaoued B3UN] UT sUOT}ENU Jayy-D 9OF-Sb ‘JO SayJo ssToape “qIUNopW (TTD) PYUayNsy IA ADOYdurA] afUOIYD aag “TTD €T ‘I90UB) ]SPIIQ ST]BISPJOUI IOJ “UTTNQIy b ‘7 ‘sTeLy [eoTUTTO LZ ‘UOHeIpel Jaye ‘uoyouNysAp af}9914 Gp ‘JaAaj pue eruadornau JoF ‘UOAUTepUT[D 9€ ‘GE ‘(AGA) SMITA Lteg-uleysdy Se ‘pe “OUIqUpr[D Tl ‘Sutsn Adezayjouisyp Jueanipe ‘uloiqnaudy @Z ‘Ia0uRd Bun] Joj ‘Aderayjourayp yuean{pe uneydsto $b ‘(OOSA) UoIsserduod p1od yeurds yeinpidy $7 ‘adURd BUNT [99 [[eUs oy 167 ‘8% ‘aprurenyezuy €Z ‘aouvd BUN] d1}e}svIOUL 10} Or ‘pue Adeloyjouayp ‘saryjedouLoopuy GZ ‘sIgdURd Yau puke peay IOJ

990 ‘SSO ‘1SZ ‘9T-Pz ‘SIaouRd YOaU puR pray 167 ‘JooUBd d}eISOId d1VBISeIDUT IOJ ‘AUOSTUpaid snqd [axejJa0q Gh ‘gI ‘aUIOIPUAS JO0J-pueH 87 ‘EZ “77 “ET “TT “‘Jaxe}a00q JSE “SE “BILUAayNg] [Jao AEH €1 ‘syBoiq pueijs-a[qnop ‘WNC H SaWAZUS (YININP) Jredas yoyeuUsTW JUSIDYeq] 9aS “MINING ZZ ‘SJUaWaInsvawWl ODOT 16% ‘a0Ukd a}e]SOId J1WeISeJOW OJ “UlJa1asOH bb °C UU TAAXOIpAUIP-ST'T 167 ‘6C-8¢ ‘Lz ‘S\stuose (HYUD) UOUWLIOY SUIsea[el-UIdomOpeuoy ¢ (SHA) SUOHeUTUTeXA [POAT [ISIC WZ ‘pue Ia9.uUed aye\so1d ‘sa1O0Ds UOsRa[D S¢-ee ‘eumoydur,y [[99-g- a81e] asNyjIGd 1 *(Stourn) [BUUOT}s [eulsajuTONses) SLSID 60 ‘SI ‘pue Aderoyjoutayp ‘eaysieiq 0z ‘(eseasip xnJor [easeydossoises) CYAD ZrO ‘1ZO ‘Er ‘MUOseyJoWexaq T ‘anss}j 10wWn) “sul[yoid sTwousy Or ‘pure AdedyJOUIdY ‘sHRULIDG TE-97 ‘Iaouerd AreULIMo}Usy 610 ‘pure drysioatains ‘uorssaidaq 0&0 ‘Zr ‘SUTTasUNOD soTJaUsy Or “87 ‘EL ‘Quutnsousd OZ ‘Ta0uRd deaIDUR IO} 16Z ‘JadULd 3}e]SO1d J17R}SPIOUL 10J *xIparesaq €T Tadd JsvaIq IPISBIOW IO} LT ‘sawAzuea (YIP) Iredar yoyeuistu yusoyoq €T ‘TZ “Jaoued Suny I0y | ‘pue sapyoid [euotjenu “suryeul UOTsIIaq 9r-Sh JO Sjoayja asJOApe (SIO) Ns UF BUOUTOIR [e}NC 2ag ‘SIOd auTqeyoWay > ‘Aq UOnIQIUU VU ‘qruayerqeq Sr ‘JO Sjoayja asTaApe ‘qrunyey qa IZ ‘(SLSTD) SIOWIN} [RWOI)s [eUTSayUTONsey tO ‘TZ ‘SIOWIN) SULIDOpUdOINAU [RUT|SaUTONSey 690 ‘Ih 'S yp ‘UT UoTssaidxa TYAH ‘s1ourny jeaseydosaoijsey ‘Spoqnur (p-V'LO) p-uesyue a]A00ydurA-], Fx0}0}AD ISO ‘Jo uoNeNyRAd ‘s1oumn) [easeydosso1sey OF ‘JO SJoa]Ja asIOApe ‘apIsOUTqRIe dUTSO]AD 0Z ‘(AUAD) esvasip xnjJear [easeydossonsey ZO ‘TE ‘Adoodsojskp OZ ‘sIaoued [Raseydossojsey L@ ‘UONCIPRI Jaqye “STTSAD 1z-0z ‘ewoydurAy ase) Tg IO} SUOTJBOTPUT ‘AUIO}D9}SA_, OF ‘JO ALOTXO} STSOTOINA|U ‘ATaSIMS ayTUY, PUTT 16Z ‘Jaoukd a7e]SO1d STVeISPISU 1OJ *“SIONQIYUL ZIAD OID ‘erwUauTTNgosewureSod Ay 10j ‘UIpNgo[s BUTTE UdUISa1 dOHO-z OS]D 2ag “ov ‘SE ‘ve ‘IL ‘apreueydsoydopasg 9 JLE ‘LE-9¢ ‘euoydurAy [[99-], snoaueynD ¢ Jo UONTUYsp ‘and eg ‘sewmmoydu] JeMoyyoy (dNd) Arewid umouyun Jo Jaoue9 aag dno +O ‘81 ‘Uatutsar XOTTOA (P-VTILO) p-Uasyue ayA00ydursT-], 1X0}O}AD 2ag *p-VTLO 16Z ‘Jaoued d}e]SOId STVeISeISUT IOJ ‘AprureNy]y TE-O€ “BWOUTOIkd [[ad [BUA IOJ ‘UOTRTqBOAID ZI ‘UOTe JO WsTURYDeU ‘SUTSxXON] (OUD) J9dUwd [kIDIIOJOD 23g ‘QYO Sp ‘JaAoj puv evluadorneu Joy ‘souojournboson[y IZO ‘onovpAydoid ‘uonerpesm [eresD OF ‘Sf ‘JO S}DayJa asTaApe ‘sauTprulsAdosonyy Or ‘uuseds A1eUOIOD be “TIO Joy ‘ourqerepny] Or ‘pue Adesoyjowlayp ‘Aouatoyynsurt ATRUOIOD UdUIB91 XOATOA OSD 22S “10 ‘OF ‘Sr ‘OZ “ST *(MA-S) [oenoiony-s 0SO ‘9T ‘UonezIuOD 990 ‘ZE ‘Sz ‘ABOfO}AD UOTJeIIdse a[paau-dUTy ¢-Z ‘pue Adesay} Jo seos ‘uot eorUNUTUOD € ‘APOFXo} [eIOUPULy 9&0 ‘ZIO ‘Aderayjoways UoTeUIquIO; € ‘puke s[eos JUSTUJeAI] ‘saNsst [eIOUPUL] LT ‘Wuaueuttad ‘AUIOso[OD 7 ‘syuawaimnseaw 'Aqy UT *6I-LT “ “(OUD) Jou [e}Da10[0D 0S0 ‘620 ‘Zr ‘ATHJet LSO ‘ST ‘Jo surseys | LSO ‘Lr ‘Ul stsouso1d €1O ‘Wealoyeap-iredar yoyeurstu Lg ‘sewoydunAT []29 J, 10J ‘stsaraydojoyd [eatodi0seNxy 9S0 ‘UI UOIssaidxa ula}01d Itedai YoyeUIsTU LZ ‘Iaoued ayeysoid 10} ‘UOT RIPRIIT Weaq [eUID}Xy IrO ‘€1O ‘oneisejou 090 ‘38 ‘Z ‘aueysoWaxy IO Jo JuswaseueUl Tg ‘sIOUIN} SULIDOpUdsOIM|U INeaIDUe IOJ ‘SNUIT[OIDAG PSO ‘Ul Sulseut Ly ‘Adeiay yusutaoe[dai ussonsy +O ‘Joy Aderayjouays 6 ‘Io} aatyIsod S][Oq ‘s10}dade1 Uas01jSy daoued UOTOD €r ‘(UOIssa1dutod p1oo [eulds Tempids) DDSA Or ‘pure AderlayOUayp ‘sHITOD Sp ‘etuadoyAd0quio1y} pue eruaue Ioj ‘uatodomyyA1q Ly ‘9p ‘UoRsuNy aayTUsOD £90 ‘Alepuodas ‘stso} A014 AIA €% ‘Jaoued B3UN] UT sUOT}ENU Jayy-D 9OF-Sb ‘JO SayJo ssToape “qIUNopW (TTD) PYUayNsy IA ADOYdurA] afUOIYD aag “TTD €T ‘I90UB) ]SPIIQ ST]BISPJOUI IOJ “UTTNQIy b ‘7 ‘sTeLy [eoTUTTO LZ ‘UOHeIpel Jaye ‘uoyouNysAp af}9914 Gp ‘JaAaj pue eruadornau JoF ‘UOAUTepUT[D 9€ ‘GE ‘(AGA) SMITA Lteg-uleysdy Se ‘pe “OUIqUpr[D Tl ‘Sutsn Adezayjouisyp Jueanipe ‘uloiqnaudy @Z ‘Ia0uRd Bun] Joj ‘Aderayjourayp yuean{pe uneydsto $b ‘(OOSA) UoIsserduod p1od yeurds yeinpidy $7 ‘adURd BUNT [99 [[eUs oy 167 ‘8% ‘aprurenyezuy €Z ‘aouvd BUN] d1}e}svIOUL 10} Or ‘pue Adeloyjouayp ‘saryjedouLoopuy GZ ‘sIgdURd Yau puke peay IOJ ‘Aq UONIQIYU YU ‘qruaye1oouy prO dno Joy 6c ‘TT ‘Supyueq oAIquiy OF ‘JO SjoaTJa asIaape Lg ‘sewoyduA] [Jad I 1OJ ‘UONeIpeL wreaq UOIDeTA 20 ‘unerdsip (AGA) SHIA Lieg-ulaysdy aag ‘Aga €€O ‘Sr ‘Taaay pue eruado nau Jo} ‘usexoyoidIp IZ ‘Z ‘WiaysAs 6FO ‘O10 Fre ‘vé ‘(T10) Bfutaynsy on ADoYydur,] otuoryD UONRZIURSIO YIeAH PLoM/dnory Asojoouo aanesiadoos; ussiseq bE “TIO Joy ‘Tonqurer0[y, a ¢ ‘s][29 | Jojdacai uasHuUR oLeUTTYyD S-p ‘oUTOTpot UoTsIoo1d bE “TIO 40 ‘qistfaanq 167 ‘Jaoued aye}s01d d1VeISeIIU IOJ Or “Ss ‘qeuInyeAinqd Og ‘Jo suoNedT[dur0d W119}-Su0] 0LO 36 “6 ‘(SIOG) MIs UI BLOUTOIeD [Jon 6ZO ‘pue sansst Ay[HI19} OL ‘pure asvasIp sJaseg ‘Jadued Jseaig [eIONG 9bF-bh JO SJoaTJo 8rO ‘ZO ‘FIO ‘8% ‘ANawondiosge AeI-x AS13Ud-;end ZO ‘T90UeRd TeUR IOJ LZ ‘(SUO}BUTWIeXd [eIDAII [eUSIP) SAAC [ ‘JO s}oayja astaape

‘Aq UONIQIYU YU ‘qruaye1oouy prO dno Joy 6c ‘TT ‘Supyueq oAIquiy OF ‘JO SjoaTJa asIaape Lg ‘sewoyduA] [Jad I 1OJ ‘UONeIpeL wreaq UOIDeTA 20 ‘unerdsip (AGA) SHIA Lieg-ulaysdy aag ‘Aga €€O ‘Sr ‘Taaay pue eruado nau Jo} ‘usexoyoidIp IZ ‘Z ‘WiaysAs 6FO ‘O10 Fre ‘vé ‘(T10) Bfutaynsy on ADoYydur,] otuoryD UONRZIURSIO YIeAH PLoM/dnory Asojoouo aanesiadoos; ussiseq bE “TIO Joy ‘Tonqurer0[y, a ¢ ‘s][29 | Jojdacai uasHuUR oLeUTTYyD S-p ‘oUTOTpot UoTsIoo1d bE “TIO 40 ‘qistfaanq 167 ‘Jaoued aye}s01d d1VeISeIIU IOJ Or “Ss ‘qeuInyeAinqd Og ‘Jo suoNedT[dur0d W119}-Su0] 0LO 36 “6 ‘(SIOG) MIs UI BLOUTOIeD [Jon 6ZO ‘pue sansst Ay[HI19} OL ‘pure asvasIp sJaseg ‘Jadued Jseaig [eIONG 9bF-bh JO SJoaTJo 8rO ‘ZO ‘FIO ‘8% ‘ANawondiosge AeI-x AS13Ud-;end ZO ‘T90UeRd TeUR IOJ LZ ‘(SUO}BUTWIeXd [eIDAII [eUSIP) SAAC [ ‘JO s}oayja astaape ET ‘Jaoued Jseaiq d1}e}se}OW OJ syuase oLfloads os]p aag ‘AderayjowlayD €I ‘Teutosodq] 97 ‘puke Jaded aye}sO1d ‘suonEINW ZYAHO Sg ‘seumoydur,y [[a9-g a81e] asNyIp 10J 9b-Sb ‘6 ‘p qeulIxnjaD LEO ‘9p ‘JO Sjoayja asIaape Or ‘Ayyedousapeydur] [estate II ‘suisn Adeiayjousayp Juean{[pe OSO ‘OT ‘WONBZIUOD [BdTAIaD UdUIISAI (OHO OS]D 24g “UlDIqni0xOq 0SO ‘80 ‘JOT ‘ZI-ST Taos [eotAraD

ET ‘Jaoued Jseaiq d1}e}se}OW OJ syuase oLfloads os]p aag ‘AderayjowlayD €I ‘Teutosodq] 97 ‘puke Jaded aye}sO1d ‘suonEINW ZYAHO Sg ‘seumoydur,y [[a9-g a81e] asNyIp 10J 9b-Sb ‘6 ‘p qeulIxnjaD LEO ‘9p ‘JO Sjoayja asIaape Or ‘Ayyedousapeydur] [estate II ‘suisn Adeiayjousayp Juean{[pe OSO ‘OT ‘WONBZIUOD [BdTAIaD UdUIISAI (OHO OS]D 24g “UlDIqni0xOq 0SO ‘80 ‘JOT ‘ZI-ST Taos [eotAraD xepul

Index Helicobacter pylori infection, 21, 34 Lumbar puncture, contraindications to, 43 Hematopoietic stem cell transplantation (HSCT), 33, 36 Lung cancers, 21-25, Q17, Q55. See also Specific cancers Hematuria, bladder cancer and, 31 Lymphadenopathy, lymphomas and, 32 Hemolytic uremic syndrome, chemotherapy and, 46 Lymphoblastic lymphomas, 37 Hemorrhagic cysts, chemotherapy and, 46 Lymphoid malignancies, 31-39 Hepatic arterial embolization, NET progression and, 21 Lymphomas, 20-21, 32. See also Specific lymphomas Hepatitis, chemotherapy and, 46 Lymphomatoid polyposis, 36 Hepatitis C virus, lymphoma and, 32 Lynch syndrome, 14, 17, 26, Q56 HER2-positive breast cancer, treatment of, 11, 13-14, Q67. See also Breast cancer M Hilar lymph nodes, 23 Magnetic resonance cholangiopancreatography, 19 Histrelin, for metastatic prostate cancer, 29t Magnetic resonance imaging (MRI), 17, 25 HIV infection, 32, 36 Malignant lymphomas, 32 HL. See Hodgkin lymphoma (HL) Malignant pericardial effusions, 43-44 Hodgkin lymphoma (HL), 32, 37-39, 38f, Q35, Q36 Malignant pleural effusions, 43-44 Hormone receptor-negative breast cancer, 11 MALT. See Mucosa-associated lymphoid tissue lymphoma (MALT) Hormone receptor-positive breast cancer, 10-11 Mammography, 7. 12 Hospice care, indications for, Q25 Mantle cell lymphomas, 36 HOXB13 mutations, prostate cancer and, 26 Mastectomy, 9, 12 HPV. See Human papillomavirus (HPV) Mediastinal large cell lymphoma, 36 HSCT. See Hematopoietic stem cell transplantation (HSCT) Mediastinal lymph nodes, 23 B-human chorionic gonadotropin marker for testicular cancer, 29-30 Melanoma, 40-42 Human epidermal growth factor 2. See also HER2 entries CTLA-4 antibodies against, 5 Human epidermal growth factor2 (HER2) mutations, 4, 7, 20, Q51 metastatic, Q28, Q69 Human herpesvirus 8, primary effusion lymphoma and, 32 nivolumab for, 5 Human papillomavirus (HPV), 16, 19, 25 surgical resection in, Q28 Human T-cell lymphotropic virus type 1, 32 surveillance in, Q72 Hypercalcemia of malignancy, 44, Q43 treatment of, 41-42 Hypercoagulability, pancreatic cancer and, 19 V600 BRAF mutation, 4 Hypertension, chemotherapy and, 46 Menopause, premature, 47 Hyperventilation, for increased ICP, 43 Meropenem, for neutropenia and fever, 45 Hypogammaglobulinemia, 35, Q10 Metastatic breast cancer, 13-14 Hypophysitis, chemotherapy and, 46 Metastatic lung cancer, 23 Hypothyroidism, Q53 Metastatic prostate cancer, 29t Methylprednisolone, for diarrhea related to immunotherapy, Q9 I Metronidazole, for neutropenia and fever, 45 Ibrutinib, for CLL, 34 Microsatellite instability (MSI), 17, 20, 28, 39 Idelalisib, for CLL, 34 Mismatch repair (MMR) genes, 14 Ifosfamide, adverse effects of, 46 Mismatch repair proteins, Q56 Imatinib, for GISTs, 21 Mitomycin, adverse effects of, 46 Immune checkpoint inhibitors, 1, 19, 20, 41, 46 Monoclonal antibodies, 34. See also Specific immunotherapy; Immune checkpoints, identification of, 5 Specific monoclonals Immune surveillance, strengthening of, 1 Moxetumomab pasudotox-tdfk, 35 Immunotherapy Mucosa-associated lymphoid tissue lymphoma (MALT), 20-21, 34, Q32 adverse effects of, Q9 Mucositis, chemotherapy and, 18 for metastatic lung cancer, Q17 Multigene recurrence assays, Q45 progress in, 5 Multiple myeloma, bone loss in, 46 for small cell lung cancer, 24 MYC rearrangement, 36 Improvements, interpretation of, 3 Mycosis fungoides, 36-37, 37f Indolent B-cell lymphomas, 33-35 Myelosuppression, chemotherapy and, 44 Infertility, cancer treatments and, 47 Inflammatory breast cancer, 12, Q40. See also Breast cancer N Inguinal lymphadenopathy, 40, Q18 Nausea and vomiting, 45, Q42 Intracranial pressure (ICP), increased, 43, Q21 Nephrectomy, for renal cell carcinoma, 30-31 Intravesical bacillus Calmette-Guérin therapy, 31 Netupitant, for nausea and vomiting, 45 Invasive breast cancer, 9-10, Q67. See also Breast cancer Neuritis, chemotherapy and, 46 Ipilimumab, 5, 41, 46 Neuroendocrine tumors, 21, Q61 Irinotecan, 18, 20 Neurokinin-1 receptor blockers, 45 Islet cell tumors. See Pancreatic neuroendocrine tumors Neutropenia, chemotherapy and, 18 Isolated regional lymphadenopathy, 40 Neutropenia and fever, 45, Q33 Ixabepilone, for metastatic breast cancer, 13 NHL. See Non-Hodgkin lymphomas (NHL) Nilotinib, adverse effects of, 46 K Nitrosureas, pulmonary toxicity of, 45-46 Kaposi sarcoma herpes virus, 32 Nivolumab Karnofsky Performance Status, 2t adverse effects of, 46 Kidney function, effects of cisplatin on, 46 for gastroesophageal cancers, 20 KRAS mutations, 4, 18-19 for melanoma, 41 for metastatic CRC, 19 L PD-1 receptor blocked by, 5 Lactate dehydrogenase (LDH) levels, staging using, 34, 36, Q6 Non-Hodgkin lymphomas (NHL), 32-37, Q18 Lambert-Eaton myasthenia, small cell lung cancer and, 24 Nonseminomatous germ cell tumors, testicular, 30 Lanreotide, NET progression and, 21 Non-small cell lung cancers (NSCLCs), 5, 22-24, Q17, Q27, Q46, Q52 Laparotomy, second-look, 14 NRAS mutations, 4, 18-19 Large B-cell lymphoma, staging of, Q6 NSCLCs. See Non-small cell lung cancers (NSCLCs) Large cell lymphomas, CLL transformation to, 35 Lenalidomide, 33, 36 O Leucovorin, 18, 20. See also FOLFOX regimen Obesity, risk of gastroesophageal cancer, 20 Leuprolide, for metastatic prostate cancer, 29t Obinutuzumab, for CLL, 34 Levofloxacin, for neutropenia and fever, 45 Octreotide, to slow NET progression, 21 Liquid biopsies, 4 Ofatumumab, for CLL, 34 Liver metastases, resection of, Q41 OFS (ovarian function suppression), 10 Lobular carcinoma in situ, breast cancer and, 5 Olanzapine, for nausea and vomiting, 45, Q42

Helicobacter pylori infection, 21, 34 Lumbar puncture, contraindications to, 43 Hematopoietic stem cell transplantation (HSCT), 33, 36 Lung cancers, 21-25, Q17, Q55. See also Specific cancers Hematuria, bladder cancer and, 31 Lymphadenopathy, lymphomas and, 32 Hemolytic uremic syndrome, chemotherapy and, 46 Lymphoblastic lymphomas, 37 Hemorrhagic cysts, chemotherapy and, 46 Lymphoid malignancies, 31-39 Hepatic arterial embolization, NET progression and, 21 Lymphomas, 20-21, 32. See also Specific lymphomas Hepatitis, chemotherapy and, 46 Lymphomatoid polyposis, 36 Hepatitis C virus, lymphoma and, 32 Lynch syndrome, 14, 17, 26, Q56 HER2-positive breast cancer, treatment of, 11, 13-14, Q67. See also Breast cancer M Hilar lymph nodes, 23 Magnetic resonance cholangiopancreatography, 19 Histrelin, for metastatic prostate cancer, 29t Magnetic resonance imaging (MRI), 17, 25 HIV infection, 32, 36 Malignant lymphomas, 32 HL. See Hodgkin lymphoma (HL) Malignant pericardial effusions, 43-44 Hodgkin lymphoma (HL), 32, 37-39, 38f, Q35, Q36 Malignant pleural effusions, 43-44 Hormone receptor-negative breast cancer, 11 MALT. See Mucosa-associated lymphoid tissue lymphoma (MALT) Hormone receptor-positive breast cancer, 10-11 Mammography, 7. 12 Hospice care, indications for, Q25 Mantle cell lymphomas, 36 HOXB13 mutations, prostate cancer and, 26 Mastectomy, 9, 12 HPV. See Human papillomavirus (HPV) Mediastinal large cell lymphoma, 36 HSCT. See Hematopoietic stem cell transplantation (HSCT) Mediastinal lymph nodes, 23 B-human chorionic gonadotropin marker for testicular cancer, 29-30 Melanoma, 40-42 Human epidermal growth factor 2. See also HER2 entries CTLA-4 antibodies against, 5 Human epidermal growth factor2 (HER2) mutations, 4, 7, 20, Q51 metastatic, Q28, Q69 Human herpesvirus 8, primary effusion lymphoma and, 32 nivolumab for, 5 Human papillomavirus (HPV), 16, 19, 25 surgical resection in, Q28 Human T-cell lymphotropic virus type 1, 32 surveillance in, Q72 Hypercalcemia of malignancy, 44, Q43 treatment of, 41-42 Hypercoagulability, pancreatic cancer and, 19 V600 BRAF mutation, 4 Hypertension, chemotherapy and, 46 Menopause, premature, 47 Hyperventilation, for increased ICP, 43 Meropenem, for neutropenia and fever, 45 Hypogammaglobulinemia, 35, Q10 Metastatic breast cancer, 13-14 Hypophysitis, chemotherapy and, 46 Metastatic lung cancer, 23 Hypothyroidism, Q53 Metastatic prostate cancer, 29t Methylprednisolone, for diarrhea related to immunotherapy, Q9 I Metronidazole, for neutropenia and fever, 45 Ibrutinib, for CLL, 34 Microsatellite instability (MSI), 17, 20, 28, 39 Idelalisib, for CLL, 34 Mismatch repair (MMR) genes, 14 Ifosfamide, adverse effects of, 46 Mismatch repair proteins, Q56 Imatinib, for GISTs, 21 Mitomycin, adverse effects of, 46 Immune checkpoint inhibitors, 1, 19, 20, 41, 46 Monoclonal antibodies, 34. See also Specific immunotherapy; Immune checkpoints, identification of, 5 Specific monoclonals Immune surveillance, strengthening of, 1 Moxetumomab pasudotox-tdfk, 35 Immunotherapy Mucosa-associated lymphoid tissue lymphoma (MALT), 20-21, 34, Q32 adverse effects of, Q9 Mucositis, chemotherapy and, 18 for metastatic lung cancer, Q17 Multigene recurrence assays, Q45 progress in, 5 Multiple myeloma, bone loss in, 46 for small cell lung cancer, 24 MYC rearrangement, 36 Improvements, interpretation of, 3 Mycosis fungoides, 36-37, 37f Indolent B-cell lymphomas, 33-35 Myelosuppression, chemotherapy and, 44 Infertility, cancer treatments and, 47 Inflammatory breast cancer, 12, Q40. See also Breast cancer N Inguinal lymphadenopathy, 40, Q18 Nausea and vomiting, 45, Q42 Intracranial pressure (ICP), increased, 43, Q21 Nephrectomy, for renal cell carcinoma, 30-31 Intravesical bacillus Calmette-Guérin therapy, 31 Netupitant, for nausea and vomiting, 45 Invasive breast cancer, 9-10, Q67. See also Breast cancer Neuritis, chemotherapy and, 46 Ipilimumab, 5, 41, 46 Neuroendocrine tumors, 21, Q61 Irinotecan, 18, 20 Neurokinin-1 receptor blockers, 45 Islet cell tumors. See Pancreatic neuroendocrine tumors Neutropenia, chemotherapy and, 18 Isolated regional lymphadenopathy, 40 Neutropenia and fever, 45, Q33 Ixabepilone, for metastatic breast cancer, 13 NHL. See Non-Hodgkin lymphomas (NHL) Nilotinib, adverse effects of, 46 K Nitrosureas, pulmonary toxicity of, 45-46 Kaposi sarcoma herpes virus, 32 Nivolumab Karnofsky Performance Status, 2t adverse effects of, 46 Kidney function, effects of cisplatin on, 46 for gastroesophageal cancers, 20 KRAS mutations, 4, 18-19 for melanoma, 41 for metastatic CRC, 19 L PD-1 receptor blocked by, 5 Lactate dehydrogenase (LDH) levels, staging using, 34, 36, Q6 Non-Hodgkin lymphomas (NHL), 32-37, Q18 Lambert-Eaton myasthenia, small cell lung cancer and, 24 Nonseminomatous germ cell tumors, testicular, 30 Lanreotide, NET progression and, 21 Non-small cell lung cancers (NSCLCs), 5, 22-24, Q17, Q27, Q46, Q52 Laparotomy, second-look, 14 NRAS mutations, 4, 18-19 Large B-cell lymphoma, staging of, Q6 NSCLCs. See Non-small cell lung cancers (NSCLCs) Large cell lymphomas, CLL transformation to, 35 Lenalidomide, 33, 36 O Leucovorin, 18, 20. See also FOLFOX regimen Obesity, risk of gastroesophageal cancer, 20 Leuprolide, for metastatic prostate cancer, 29t Obinutuzumab, for CLL, 34 Levofloxacin, for neutropenia and fever, 45 Octreotide, to slow NET progression, 21 Liquid biopsies, 4 Ofatumumab, for CLL, 34 Liver metastases, resection of, Q41 OFS (ovarian function suppression), 10 Lobular carcinoma in situ, breast cancer and, 5 Olanzapine, for nausea and vomiting, 45, Q42 107

sOoL Ov ‘JO AYDIXO} SISOTOINSU ‘AIISINSOIPeI 91}De}OIIAIS FE “TIO Joy ‘sanSoyeur aptsoajonu suLtng 7SO ‘Adeiay] UoTeIpes 919k}0910}$ Op ‘puke AderoyOWDY ‘uolsua}tod Ay ArevuourNng rz ‘Uonerpeit Apog a99e}00101S$ 9b-Sh ‘JO SIopsOsIp ‘UoTouNy AreuowyNg T ‘pure sadtoyp jusurtyeaI} Lg ‘suaye1osg LSO ‘pure stsousoid (VSd) Uasnue syTads-a}e}so1g 33S "WSd I ‘UI sansst OF ‘JO SJOaIJo ISIOAPR “SIOJIGIUUT aULOSka}0Ig T ‘pue surseult Zé “else[doau [erayydoenur oneisolg SUIseIS 890 ‘8&0 ‘8z “BUISN ddUeTTIAAINs SZ-€T ‘OT ‘(SODS) SBUOUTOIRO []29 snourenbs WZ ‘LT-9Z ‘pure SIsOUBeIp 1adUed 3}e}s01d Ze ‘puke ADH ‘ewoydur{] ouoz [eursieur stuayds (VSd) UestyuR syoads-aye}soig €90 ‘Er ‘UoTssaidutos prod peutds 8c-Le “[eorpea ‘AUIO}9918ISOIg T ‘WiaysAs SUTSeIS JAN ‘SIOUWUN} pI[os 890 ‘6£0 ‘8EO ‘OO ‘162 ‘67-97 “JooURD ayRISOIg ZZ ‘JO SJouaq ‘UOTJessad SUP{OUIS Z ‘Autoyda10Yydoo-osuldyes [er19}e[Iq sovyAydorg SZ ‘O07 ‘PUB YS Jo.Ukd ‘SUPjOUIS or ‘Ayjedojeydaousaoyngy [RooyH[NU datsso1BOIg IZO ‘¥@ “(SOTOS) Ja0uRd Suny [[20 [[eWUS LVO ‘€ ‘[RATAINS 3a1J-UOIssa1B01g LE-9¢€ ‘pur seutoydur] [Ja |, 6€ ‘TE “EZ ‘JOT “ET “s ‘SoTpoqnue ([]-dd) Pues | yeep pourtueIs01g Th-OP ‘PUIOURToUT 690 ‘E10 ‘92 ‘EZ ‘OZ “OT ‘S ‘sarpoqnue (T-qd) I Uap pautuess01g uns LSO ‘pue Buses ‘slsousoIg ze ‘pue euroydursy ‘aworpuds usi1sels Zé ‘pure g snatAsadiey UeWINyY ‘ewoYdurAy UOIsnyyja AreUtLg 16Z “Ia0ued 9}e}sOId JTVeISvIOU OJ ‘[-Jaonatndis 910 ‘sansst diysioatains ‘AouvuBeig € ‘TRATAINS UT JUSWIDAOIGUT JURIYTUBIS UdUIS91 (OHD-Y OS]D ag “SE ‘9Z ‘AUOSTUParg € Jo uonTuyap ‘aouvoyiusis Or ‘oWOIpUAS Ayedopeydaoud IoL10}sog LE-9¢ ‘aulorpuAs A1eZ3S OF ‘JO SJOaJJa asIaape ‘qruNeUod Lp ‘pue syusutjeay) Iaaued ‘uonouTy [enxas SIO ‘Ader9y} JOQIYyUT aserauAod (asoqhi-qqy) AfOod Th-Tr ‘01-6 ‘salsdorq apou Jaunuas 9Ob-Sr ‘shtuoutnoug Og ‘Te[NDIsSo} ‘SeULOUTUUaS 6SO0 ‘9bO ‘hr-€r ‘SUOIsNyJe [ena] q O€-6z ‘punoseI}{N [e}]019S PI ‘ooUvd URLTeAO 10} ‘AdersyOWsYS suexe}-WMUYe]g (SOTOS) Jaoueo Bunt [J99 [Teg aag *SOTOS pZ ‘IaoUed SUN] [[Pd [TeUIs Ioy ‘aprsodoja-tunuTyeTg (SQOS) SPUIOUTOIeD [Jad snoutenbs aag *soNS 80 ‘Or ‘sjuase WMNUyeId Z ‘Terayepig ade[Aydoud ‘Autojda10ydoo-osurdyes Sr ‘JoAgy pue efuadoInau oj ‘wueJDeqoze}/UTT[IoeIadIg § FE “TID JO} ‘SIOJQIYUT aseUTy ¢-apHtsouroydsoyg Gz ‘s1a0Ued YoU pure peat Ul ‘LD/LAd €Z ‘Jaouevd BUN] UT ‘suONeNU ISOM €1 ‘TL ‘Jooued Jsvoiq aattsod-z7yqH oJ ‘qeuinzn}1ag 9r-Sr ‘JO AVOTxo} Areuowynd Of ‘USWIOM UT ‘sTSO}BWIOUTOIvO [RIUO}LIAg 9¢ ‘eUTOYCUIA] [[99 S]VURLL IOJ Lg ‘payoads astmiayjo Jou ‘seuroydur{] [Jao |, eraydiiag ZEO “BUNT SUTATOAU! [TV 10} Or ‘ST ‘pue Adesayjoutayp ‘Ayjedoinau [eraydiiag 6g ‘eWOYdUIA] UP{SpoH OJ €p ‘Snoauend1ad ‘sisa]UIIOIPIBILIIg SE “eIULaYNJy [Jao ATey Oy br-€h ‘SUOISNJJo [RIPIRILIEg eg ‘euoydurAy re[NdT[O} Oy 1Z ‘ZT ‘sM}BIS DUBULIOJ.10g cg ‘seumoydur(] [[99-g adIe[ asNYIp oy Ep ‘SISa}UdDOIpIedLiad snosuend13g bE “TIO 40F Tz ‘Adesayjorpes 10}da9a1-apndag 9¢ ‘ewoydurAy WAN Oy SE ‘PE ‘UNPISOWad 9p ‘JO sjDayja asIaape €% ‘ZZ ‘Jaoued BUN] IOJ ‘paxanjawuiag UdWISa1 GOHD-z OS]D aag ‘qeulixniTy 9¢ ‘sIadURd YIU PUR Peay JUILIMIAL 10J €-Z ‘pur sjeos JuswyeAI} § ‘Aq paysoyq 10}dadaI T-dd > ‘AYOIXO} SA Adeoyya LIO ‘OTOSN 104 sIsyeuR s}Jouaq/YSTY 8z ‘Taoued 3}e)}so1d oT}eISeIOU JOT SE “UONeULIOJsURI} JaYOTY LIO ‘“JoouRd SUNT d1}eISe}IUT IOJ ze ‘pue euoydw{] ‘(vy) sHyIIe ployeumsayy 61 ‘ONO PJSP}OU TOF 0€ ‘(ANTdu) UONdassip apou YdurAy [eauoyiadosy Tr ‘eUouRyaut 10} € Jo UoTTUYap ‘sayer asuodsay 0Z ‘SI90URd [easeydosaoises 10} £90 ‘TE-O& ‘*S “(ODM) PULOUTOIRO [Jao [RUDY OF JO S]OaTJa as1OApe

Ov ‘JO AYDIXO} SISOTOINSU ‘AIISINSOIPeI 91}De}OIIAIS FE “TIO Joy ‘sanSoyeur aptsoajonu suLtng 7SO ‘Adeiay] UoTeIpes 919k}0910}$ Op ‘puke AderoyOWDY ‘uolsua}tod Ay ArevuourNng rz ‘Uonerpeit Apog a99e}00101S$ 9b-Sh ‘JO SIopsOsIp ‘UoTouNy AreuowyNg T ‘pure sadtoyp jusurtyeaI} Lg ‘suaye1osg LSO ‘pure stsousoid (VSd) Uasnue syTads-a}e}so1g 33S "WSd I ‘UI sansst OF ‘JO SJOaIJo ISIOAPR “SIOJIGIUUT aULOSka}0Ig T ‘pue surseult Zé “else[doau [erayydoenur oneisolg SUIseIS 890 ‘8&0 ‘8z “BUISN ddUeTTIAAINs SZ-€T ‘OT ‘(SODS) SBUOUTOIRO []29 snourenbs WZ ‘LT-9Z ‘pure SIsOUBeIp 1adUed 3}e}s01d Ze ‘puke ADH ‘ewoydur{] ouoz [eursieur stuayds (VSd) UestyuR syoads-aye}soig €90 ‘Er ‘UoTssaidutos prod peutds 8c-Le “[eorpea ‘AUIO}9918ISOIg T ‘WiaysAs SUTSeIS JAN ‘SIOUWUN} pI[os 890 ‘6£0 ‘8EO ‘OO ‘162 ‘67-97 “JooURD ayRISOIg ZZ ‘JO SJouaq ‘UOTJessad SUP{OUIS Z ‘Autoyda10Yydoo-osuldyes [er19}e[Iq sovyAydorg SZ ‘O07 ‘PUB YS Jo.Ukd ‘SUPjOUIS or ‘Ayjedojeydaousaoyngy [RooyH[NU datsso1BOIg IZO ‘¥@ “(SOTOS) Ja0uRd Suny [[20 [[eWUS LVO ‘€ ‘[RATAINS 3a1J-UOIssa1B01g LE-9¢€ ‘pur seutoydur] [Ja |, 6€ ‘TE “EZ ‘JOT “ET “s ‘SoTpoqnue ([]-dd) Pues | yeep pourtueIs01g Th-OP ‘PUIOURToUT 690 ‘E10 ‘92 ‘EZ ‘OZ “OT ‘S ‘sarpoqnue (T-qd) I Uap pautuess01g uns LSO ‘pue Buses ‘slsousoIg ze ‘pue euroydursy ‘aworpuds usi1sels Zé ‘pure g snatAsadiey UeWINyY ‘ewoYdurAy UOIsnyyja AreUtLg 16Z “Ia0ued 9}e}sOId JTVeISvIOU OJ ‘[-Jaonatndis 910 ‘sansst diysioatains ‘AouvuBeig € ‘TRATAINS UT JUSWIDAOIGUT JURIYTUBIS UdUIS91 (OHD-Y OS]D ag “SE ‘9Z ‘AUOSTUParg € Jo uonTuyap ‘aouvoyiusis Or ‘oWOIpUAS Ayedopeydaoud IoL10}sog LE-9¢ ‘aulorpuAs A1eZ3S OF ‘JO SJOaJJa asIaape ‘qruNeUod Lp ‘pue syusutjeay) Iaaued ‘uonouTy [enxas SIO ‘Ader9y} JOQIYyUT aserauAod (asoqhi-qqy) AfOod Th-Tr ‘01-6 ‘salsdorq apou Jaunuas 9Ob-Sr ‘shtuoutnoug Og ‘Te[NDIsSo} ‘SeULOUTUUaS 6SO0 ‘9bO ‘hr-€r ‘SUOIsNyJe [ena] q O€-6z ‘punoseI}{N [e}]019S PI ‘ooUvd URLTeAO 10} ‘AdersyOWsYS suexe}-WMUYe]g (SOTOS) Jaoueo Bunt [J99 [Teg aag *SOTOS pZ ‘IaoUed SUN] [[Pd [TeUIs Ioy ‘aprsodoja-tunuTyeTg (SQOS) SPUIOUTOIeD [Jad snoutenbs aag *soNS 80 ‘Or ‘sjuase WMNUyeId Z ‘Terayepig ade[Aydoud ‘Autojda10ydoo-osurdyes Sr ‘JoAgy pue efuadoInau oj ‘wueJDeqoze}/UTT[IoeIadIg § FE “TID JO} ‘SIOJQIYUT aseUTy ¢-apHtsouroydsoyg Gz ‘s1a0Ued YoU pure peat Ul ‘LD/LAd €Z ‘Jaouevd BUN] UT ‘suONeNU ISOM €1 ‘TL ‘Jooued Jsvoiq aattsod-z7yqH oJ ‘qeuinzn}1ag 9r-Sr ‘JO AVOTxo} Areuowynd Of ‘USWIOM UT ‘sTSO}BWIOUTOIvO [RIUO}LIAg 9¢ ‘eUTOYCUIA] [[99 S]VURLL IOJ Lg ‘payoads astmiayjo Jou ‘seuroydur{] [Jao |, eraydiiag ZEO “BUNT SUTATOAU! [TV 10} Or ‘ST ‘pue Adesayjoutayp ‘Ayjedoinau [eraydiiag 6g ‘eWOYdUIA] UP{SpoH OJ €p ‘Snoauend1ad ‘sisa]UIIOIPIBILIIg SE “eIULaYNJy [Jao ATey Oy br-€h ‘SUOISNJJo [RIPIRILIEg eg ‘euoydurAy re[NdT[O} Oy 1Z ‘ZT ‘sM}BIS DUBULIOJ.10g cg ‘seumoydur(] [[99-g adIe[ asNYIp oy Ep ‘SISa}UdDOIpIedLiad snosuend13g bE “TIO 40F Tz ‘Adesayjorpes 10}da9a1-apndag 9¢ ‘ewoydurAy WAN Oy SE ‘PE ‘UNPISOWad 9p ‘JO sjDayja asIaape €% ‘ZZ ‘Jaoued BUN] IOJ ‘paxanjawuiag UdWISa1 GOHD-z OS]D aag ‘qeulixniTy 9¢ ‘sIadURd YIU PUR Peay JUILIMIAL 10J €-Z ‘pur sjeos JuswyeAI} § ‘Aq paysoyq 10}dadaI T-dd > ‘AYOIXO} SA Adeoyya LIO ‘OTOSN 104 sIsyeuR s}Jouaq/YSTY 8z ‘Taoued 3}e)}so1d oT}eISeIOU JOT SE “UONeULIOJsURI} JaYOTY LIO ‘“JoouRd SUNT d1}eISe}IUT IOJ ze ‘pue euoydw{] ‘(vy) sHyIIe ployeumsayy 61 ‘ONO PJSP}OU TOF 0€ ‘(ANTdu) UONdassip apou YdurAy [eauoyiadosy Tr ‘eUouRyaut 10} € Jo UoTTUYap ‘sayer asuodsay 0Z ‘SI90URd [easeydosaoises 10} £90 ‘TE-O& ‘*S “(ODM) PULOUTOIRO [Jao [RUDY OF JO S]OaTJa as1OApe J8E “SE ‘S[[29 BIAqULII}S-PI2y qeumzqpoiquiag } ‘JO Ysl SulAyQUApt ‘sduaTIMIay JTL ‘ZI ‘soueseadde asueiop nead,, 790 ‘8SO ‘SI-LI ‘Joouea [ejay (I-dd) I wap paurtuessold ag “T-dd 9€ “SE ‘UdUIs91 (OHO-A tr ‘UId}01d pa}efaI-duOUIOY prlorAyered (QOU) BULOUTOID [99 [RUDY 94g ‘OOW Og ‘pure Dox ‘saworpuAs oNse[dooueieg 9¢O ‘puke UoNUaAaId STL ‘aseoLIngsey Sb 6T ‘bp ‘qeummnurimyrued p ‘Sulssaidxa s1ourn) ‘suole Mul SYY 190 ‘Iz ‘SIOWIN] sUTIDOpUdOIN|U Jesu Oz ‘SiaouRd [easeydossorjses oF ‘qeunsToNueY 190 ‘OZ-6I “aud dIRaIDURg 18 ‘ZL “OUsyIXO[eY Sp ‘SUIJIWUOA pure vasneU Joj ‘UoMasouo[edg 16¢ “87 ‘Ecc-WUNIpey bI-€T ‘leo oArye led Tz ‘pue uorssaisoid [AN ‘Uonriqe Asuanbayoipey, OL ‘}SBa1q dy} JO asvasIp sjaseg OS ‘AurodaTayoe.y [eoIpey, TT ‘Suysn Adesayjourayp yuean{pe ‘Jaxer Té-0¢ ‘Auto}a1ydou [eorpey cz ‘BuTUTeIS OT ILO ‘0-62 ‘AWWO}DATYIIO [eUINSUT [eoIpey d OL ‘Jsvarg apoyM LZ ‘Iaoued ayeysoid oy UsUNISa1 XOATOA ‘UsuIsal XOdVO OS]D 2a$ ‘TO ‘Or ‘Oz ‘ST ‘UNe[dyexO Ob-Sp ‘pue situowMesud € JO UONTUYap ‘TRATAINS [[eI9AQ Or JO AYIOIXO} SIBoToInsu Ly ‘JO Sjajjo osroape ‘uorssaiddns ueLieVAaOQ €SO ‘0} pojlefer WsIplo1AyjodAy OT ‘(SAO) UorIsseiddns uoNsuny ueLTeAG 8O “Jaded [BITAIIO YSLI-YSIY Joy S90 ‘SIO ‘ZO ‘IST “ST-FI “Tooued ULTRA, SZ ‘SIaoUR YoU pure pRoy IOf 8hO ‘€ZO ‘9F ‘sIsoIodoa\scC eg “BULOYdUA] e[NdTO} OJ JOP “SISOIDIU09}SQ ZO ‘T9dUBd [BU IO} 8z ‘UTed JU0g 10F ‘sIOJIQIYUT svpooa]scEC, 6 ‘SIOG 407 Arasims sdye. Eb dO] pasvaroul Ioj ‘sisamip oyoutsO 6 “I20UBd JSBIIq JATSBAUT JO UOISTOXa Jaye GZ ‘SIo0UBd [RosUAIeYdo.IO Adeiay) uoneipey 670 ‘IT ‘SuppuRq 214900 97 ‘pure Ia.ued 9}e}so1d ZrO ‘Shr ‘BUNTWIOA puke vasneu JI0j ‘UOMasURepPUuO Ze ‘pue ewoyduAy yong [ ‘sanss] Surse}s ‘Aso;OIUQ Ajforuyja/a0ey br-Zr ‘SatoUasIN JISOTOIUD u pL ‘er ‘quede[o

J8E “SE ‘S[[29 BIAqULII}S-PI2y qeumzqpoiquiag } ‘JO Ysl SulAyQUApt ‘sduaTIMIay JTL ‘ZI ‘soueseadde asueiop nead,, 790 ‘8SO ‘SI-LI ‘Joouea [ejay (I-dd) I wap paurtuessold ag “T-dd 9€ “SE ‘UdUIs91 (OHO-A tr ‘UId}01d pa}efaI-duOUIOY prlorAyered (QOU) BULOUTOID [99 [RUDY 94g ‘OOW Og ‘pure Dox ‘saworpuAs oNse[dooueieg 9¢O ‘puke UoNUaAaId STL ‘aseoLIngsey Sb 6T ‘bp ‘qeummnurimyrued p ‘Sulssaidxa s1ourn) ‘suole Mul SYY 190 ‘Iz ‘SIOWIN] sUTIDOpUdOIN|U Jesu Oz ‘SiaouRd [easeydossorjses oF ‘qeunsToNueY 190 ‘OZ-6I “aud dIRaIDURg 18 ‘ZL “OUsyIXO[eY Sp ‘SUIJIWUOA pure vasneU Joj ‘UoMasouo[edg 16¢ “87 ‘Ecc-WUNIpey bI-€T ‘leo oArye led Tz ‘pue uorssaisoid [AN ‘Uonriqe Asuanbayoipey, OL ‘}SBa1q dy} JO asvasIp sjaseg OS ‘AurodaTayoe.y [eoIpey, TT ‘Suysn Adesayjourayp yuean{pe ‘Jaxer Té-0¢ ‘Auto}a1ydou [eorpey cz ‘BuTUTeIS OT ILO ‘0-62 ‘AWWO}DATYIIO [eUINSUT [eoIpey d OL ‘Jsvarg apoyM LZ ‘Iaoued ayeysoid oy UsUNISa1 XOATOA ‘UsuIsal XOdVO OS]D 2a$ ‘TO ‘Or ‘Oz ‘ST ‘UNe[dyexO Ob-Sp ‘pue situowMesud € JO UONTUYap ‘TRATAINS [[eI9AQ Or JO AYIOIXO} SIBoToInsu Ly ‘JO Sjajjo osroape ‘uorssaiddns ueLieVAaOQ €SO ‘0} pojlefer WsIplo1AyjodAy OT ‘(SAO) UorIsseiddns uoNsuny ueLTeAG 8O “Jaded [BITAIIO YSLI-YSIY Joy S90 ‘SIO ‘ZO ‘IST “ST-FI “Tooued ULTRA, SZ ‘SIaoUR YoU pure pRoy IOf 8hO ‘€ZO ‘9F ‘sIsoIodoa\scC eg “BULOYdUA] e[NdTO} OJ JOP “SISOIDIU09}SQ ZO ‘T9dUBd [BU IO} 8z ‘UTed JU0g 10F ‘sIOJIQIYUT svpooa]scEC, 6 ‘SIOG 407 Arasims sdye. Eb dO] pasvaroul Ioj ‘sisamip oyoutsO 6 “I20UBd JSBIIq JATSBAUT JO UOISTOXa Jaye GZ ‘SIo0UBd [RosUAIeYdo.IO Adeiay) uoneipey 670 ‘IT ‘SuppuRq 214900 97 ‘pure Ia.ued 9}e}so1d ZrO ‘Shr ‘BUNTWIOA puke vasneu JI0j ‘UOMasURepPUuO Ze ‘pue ewoyduAy yong [ ‘sanss] Surse}s ‘Aso;OIUQ Ajforuyja/a0ey br-Zr ‘SatoUasIN JISOTOIUD u pL ‘er ‘quede[o xepul

Index Stomach, gastric lymphomas, 20-21 for HER2-positive breast cancer, 11, 13 Substantial improvement, interpretation of, 3 pulmonary toxicity of, 45-46 Sunitinib, 21, 31, 46 Treatment approaches, 3-5 Superior vena cava (SVC) syndrome, 42, 42f, Q59 Triple-negative breast cancer (TNBC), relapse rates in, 13 Supportive care, 3, Q25 Triptorelin, for metastatic prostate cancer, 29t Surgical resection, traditional treatment using, 4 TRK mutations, in lung cancer, 23 Survivorship issues, 46-47, Q16, Q19 Trousseau syndrome, pancreatic cancer and, 19 Syndrome of inappropriate antidiuretic hormone secretion, 24 Tumor DNA, liquid biopsies for, 4 Systemic lupus erythematosus (SLE), lymphoma and, 32 Tumor lysis syndrome (TLS), 44, Q26, Q37 Tumor vaccines, 29t T Talazoparib, in metastatic breast cancer, 13 U Tamoxifen, 7, 8t, 9, 10, 47 Urinary incontinence, after prostatectomy, 27 Taxanes, 13, 46 T-cell lymphomas, 36-37 Vv Temozolomide, for pancreatic neuroendocrine tumors, 21 V600 BRAF mutation, 4 Testicular cancer, 29-30, QU Vaccinations, HPV, 16, 19 Thoracentesis, therapeutic, 43 Vancomycin, for neutropenia and fever, 45 Thrombocytopenia, 45 Vemurafenib, 4, 35 Thyroiditis, chemotherapy and, 46 Venalfaxine, for depression, Q19 Thyroid-stimulating hormone levels, Q53 TLS. See Tumor lysis syndrome (TLS) Venetoclax, for CLL, 34 TNM staging system, 1 Venous thromboembolism, 42-43 Vinca alkaloids, adverse effects of, 46 Tobacco use, head and neck cancers and, 25 Total neoadjuvant therapy (TNT), for CRC, 17 Vincristine, 35. See also R-CHOP regimen Trachelectomy, radical, 16 Vinorelbine, 13, 22 Vitamin D, for bone loss, 46 Transrectal ultrasonography, prostate cancer and, 27 Transurethreal resection of the bladder (TURBT), 31 Transvaginal ultrasonography, diagnostic, 14 z Trastuzumab Zoledronic acid, 13, 44, Q34 HER2 inhibition by, 4, 7 Zubrod scale, 2

Stomach, gastric lymphomas, 20-21 for HER2-positive breast cancer, 11, 13 Substantial improvement, interpretation of, 3 pulmonary toxicity of, 45-46 Sunitinib, 21, 31, 46 Treatment approaches, 3-5 Superior vena cava (SVC) syndrome, 42, 42f, Q59 Triple-negative breast cancer (TNBC), relapse rates in, 13 Supportive care, 3, Q25 Triptorelin, for metastatic prostate cancer, 29t Surgical resection, traditional treatment using, 4 TRK mutations, in lung cancer, 23 Survivorship issues, 46-47, Q16, Q19 Trousseau syndrome, pancreatic cancer and, 19 Syndrome of inappropriate antidiuretic hormone secretion, 24 Tumor DNA, liquid biopsies for, 4 Systemic lupus erythematosus (SLE), lymphoma and, 32 Tumor lysis syndrome (TLS), 44, Q26, Q37 Tumor vaccines, 29t T Talazoparib, in metastatic breast cancer, 13 U Tamoxifen, 7, 8t, 9, 10, 47 Urinary incontinence, after prostatectomy, 27 Taxanes, 13, 46 T-cell lymphomas, 36-37 Vv Temozolomide, for pancreatic neuroendocrine tumors, 21 V600 BRAF mutation, 4 Testicular cancer, 29-30, QU Vaccinations, HPV, 16, 19 Thoracentesis, therapeutic, 43 Vancomycin, for neutropenia and fever, 45 Thrombocytopenia, 45 Vemurafenib, 4, 35 Thyroiditis, chemotherapy and, 46 Venalfaxine, for depression, Q19 Thyroid-stimulating hormone levels, Q53 TLS. See Tumor lysis syndrome (TLS) Venetoclax, for CLL, 34 TNM staging system, 1 Venous thromboembolism, 42-43 Vinca alkaloids, adverse effects of, 46 Tobacco use, head and neck cancers and, 25 Total neoadjuvant therapy (TNT), for CRC, 17 Vincristine, 35. See also R-CHOP regimen Trachelectomy, radical, 16 Vinorelbine, 13, 22 Vitamin D, for bone loss, 46 Transrectal ultrasonography, prostate cancer and, 27 Transurethreal resection of the bladder (TURBT), 31 Transvaginal ultrasonography, diagnostic, 14 z Trastuzumab Zoledronic acid, 13, 44, Q34 HER2 inhibition by, 4, 7 Zubrod scale, 2 109